



Paris, 8th February 2011, 5:45 pm

First US sale of masitinib in canine mast cell tumors

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the **launch of the commercialisation and the first commercial shipments of masitinib across the United States to veterinary hospitals and veterinarians.**

In the United States, masitinib is marketed under the brand name KINAVET-CA1, for the treatment of recurrent or non-resectable Grade II and Grade III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids.

KINAVET-CA1 is marketed directly by AB Science sales force, complemented by a network of three independent distributors specialized in the marketing and distribution of veterinary oncology drugs.

Masitinib was already approved by European Medicine Agency (EMA) and commercialised in Europe under the name MASIVET.

Dr Albert Ahn, President of AB Science USA declared « We recently published that masitinib treatment was shown to improve long-term survival in canine mast cell tumor, and that short-term response at 6 weeks was not predictive of long-term survival. Our goal is to continue to develop major clinical advances for veterinarians and to establish masitinib as the reference treatment for canine mast cell tumour ».

About Canine Mast Cell Tumor

Mast cell tumour (MCT), also known as a mastocytoma, is the most common cutaneous malignant neoplasm in dogs, accounting for 16 to 21% of all skin tumours. The behaviour and progression of MCTs are highly heterogeneous. They range from slow-growing tumours with a low potential for metastasis (grade I) to undifferentiated, aggressive tumours (grade II and III) with a high potential for metastasising to local lymph nodes, the liver, spleen and bone marrow

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Owing to its novel mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases and in certain diseases of the central nervous system. Through its activity of inhibiting certain kinases that are essential in some oncogenic processes, masitinib may have an effect on tumour regression, alone or in combination with chemotherapy. Through its activity on the mast cell and certain kinases essential to the activation of the inflammatory cells and fibrosing tissue remodelling, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. Masitinib, a lead compound, has already been registered in veterinary medicine in Europe and in the USA, and is pursuing nine phase 3 studies in human medicine, including five studies on-going in pancreatic cancer, GIST, in metastatic melanoma expressing JM mutation of c-Kit, in mastocytosis, and severe persistent asthma.

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realisation of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

* * *

AB Science - Financial Communication & Press Relations

Citigate
Dewe Rogerson

Contacts Citigate Dewe Rogerson :
Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr